The Federal Trade Commission (FTC) has filed a legal complaint accusing the 3 largest pharmacy benefit managers (PBMs) in the ...

Tandem and Eli Lilly carried out trials to demonstrate the advantages of using Lyumjev in combination with Control-IQ ...

Tandem Diabetes Care (Nasdaq:TNDM) announced today that it received clearance for the use of rapid-acting insulin with its ...

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, today announced that ...

As the leader of Connecticut’s #insulin4all chapter, I’ve met countless patients who have struggled to afford their insulin.

The global rapid-acting insulin market is expected to grow at a CAGR of 4.75% and reach US$ 11.17 billion by 2032, from US$ 7.36 billion in 2023. The market is mainly driven by growth rate of diabetes ...

A new class of insulin taken once a week could be just as effective for managing blood sugar in people with type 1 and type 2 ...

Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.

Findings from two US trials of efsitora, developed by pharma company Eli Lilly, have been presented at the annual meeting of ...

An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...

New research published in The Lancet and presented at this year's Annual Meeting of the European Association for the Study of Diabetes (EASD) in ...

The "Rapid Acting Insulin Market Report, Forecast by Product, Indication, Distribution Channel, Countries and Company ...